来自植物的天然产品 准勒素抵抗 为了未来的抗肥胖剂的发展
1Key Laboratory of Endocrinology of National Health Commission, Department of Endocrinology, Peking Union Medical College Hospital, Chinese Academy of Medical Science & Peking Union Medical College, Beijing, China.
Phytotherapy research : PTR
|January 4, 2025
概括
天然产品在克服瘦素耐药性方面表现有前途,瘦素耐药性是肥胖的一个关键因素. 这篇评论探讨了针对改善瘦素路径的自然化合物.
科学领域:
- 药理学和内分泌学 药理学和内分泌学
- 自然产品化学 自然产品化学
- 肥胖问题研究研究
背景情况:
- 肥胖影响全球16%的成年人,年轻人中患病率越来越高.
- 瘦素通过抑制食欲和增加能量消耗来调节体重.
- 在肥胖个体中,单独治疗勒是无效的,原因是高勒血症和勒抗性.
研究的目的:
- 审查可以改善勒素抗性的天然产品.
- 为了确定治疗目标,以增强瘦素的减肥效果.
- 在临床前和临床研究中评估天然产品的疗效.
主要方法:
- 关于天然产品和勒素耐药性的研究的文献综述.
- 对针对特定信号通路 (例如,JAK2/STAT3,PTP1B) 的自然产品的分析.
- 对实验和临床试验数据的有效性和安全性的评估.
主要成果:
- 天然产品在改善勒素耐药性方面显示出潜在的潜力.
- 几种天然化合物向涉及莱普信号传递的关键途径.
- 来自实验和有限的临床试验的证据表明有效性.
结论:
- 天然产品为治疗肥胖症的合成药物提供了一个有希望的替代品.
- 需要进一步进行高质量的临床研究,以验证研究结果,因为研究异质性和样本规模小.
- 针对勒素抗性途径的天然产品为抗肥胖剂的开发提供了新的方向.
相关概念视频
Glucagon-like Receptor Agonists
295
Incretins include glucagon-like peptide-1 (GLP-1) and glucose-dependent insulinotropic polypeptide (GIP), which stimulate insulin secretion post-meals. In type 2 diabetes, GIP's efficacy is reduced, making GLP-1 a viable drug target. GIP originates from preproGIP.
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
GLP-1, when administered in high doses intravenously, triggers insulin secretion, inhibits glucagon release, slows gastric emptying, reduces food intake, and restores normal insulin secretion. However, its rapid inactivation by...
295
Regulation of Food Intake
185
Short-term regulation of food intake primarily involves neural signals from the gastrointestinal (GI) tract, blood nutrient levels, and GI tract hormones. Communication between the gut and brain via vagal nerve fibers plays a significant role in evaluating the contents of the gut. Clinical studies have shown that protein ingestion produces a more prolonged response in these nerve fibers compared to an equivalent amount of glucose. Additionally, the activation of stretch receptors caused by GI...
185
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
152
α-glucosidase inhibitors, including acarbose (Precose), miglitol (Glyset), and voglibose (Voglib) (primarily available in Asia), are drugs that control blood sugar levels by delaying the digestion of starch and disaccharides. They achieve this by inhibiting α-glucosidase enzymes in the intestine, which slow the absorption of carbohydrates in the intestine, which in turn leads to a prolonged release of the glucoregulatory hormone GLP-1 from intestinal L-cells.
Acarbose and miglitol are...
Acarbose and miglitol are...
152
Transducer Mechanism: Enzyme-Linked Receptors
2.3K
Enzyme-linked receptors are cell-surface receptors acting as an enzyme or associating with an enzyme intracellularly. They make excellent drug targets. Drugs can bind to the extracellular ligand-binding domain or directly affect their enzymatic domain and alter their activity.
Major types that are helpful drug targets include:
Major types that are helpful drug targets include:
2.3K
Transducer Mechanism: Nuclear Receptors
1.3K
Nuclear receptors, or NRs, are unique transcription factors that regulate gene transcription and affect the cellular pathways involved in reproduction, development, or metabolism. Their ability to be stimulated by small lipophilic ligands and control vital cellular processes makes them ideal drug targets. Nearly 10-15% of currently prescribed drugs target these receptors.
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
About 48 different soluble family members of nuclear receptors are identified that can be divided into two main classes:
1.3K
Oral Hypoglycemic Agents: Biguanides and Glitazones
165
Biguanides, particularly metformin (Glucophage), are insulin sensitizers that enhance glucose uptake, thereby reducing insulin resistance. Unlike sulfonylureas, metformin doesn't prompt insulin secretion, which helps to curb hypoglycemia risk. Metformin is beneficial in treating conditions like polycystic ovary syndrome due to its insulin-resistance reduction capability. The drug's primary action involves curtailing hepatic gluconeogenesis, a significant contributor to high blood...
165


